XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors.
Roche provides update from FDA hearing on Avastin for metastatic breast cancer
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin® (bevacizumab) in combination with paclitaxel chemotherapy for previously untreated (first-line) HER2-negative metastatic breast cancer.
Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
- Details
- Category: Eli Lilly and Company
John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company (NYSE: LLY), urged that biopharmaceuticals be included in transatlantic trade and economic discussions.
Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis
- Details
- Category: Genzyme
Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced positive top-line results from CARE-MS I, the first of two randomized, Phase 3 clinical trials comparing the investigational drug alemtuzumab to the approved multiple sclerosis therapy Rebif® (high dose subcutaneous interferon beta-1a) in patients with relapsing-remitting multiple sclerosis (RRMS).
Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition
- Details
- Category: Boehringer Ingelheim
As part of a three-year global initiative to identify and support the most promising solutions to challenging health problems around the world, Boehringer Ingelheim and Ashoka's Changemakers® announced the launch of the "Making More Health" Competition.
Phase III trial of Novartis drug Afinitor® met primary endpoint
- Details
- Category: Novartis
Novartis announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)[1],[2],[6].
Pfizer to Explore Strategic Alternatives for its Animal Health and Nutrition Businesses
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value.
More Pharma News ...
- Bristol-Myers Squibb and Innate Pharma Announce Breakthrough Global License Agreement
- Amgen and UCB Team Up with NASA
- London 2012 partner, GlaxoSmithKline, shares scientific expertise with World Anti-Doping Agency
- Novartis receives FDA approval for Arcapta(TM) Neohaler(TM)
- Pfizer and ChemRar to Explore Innovative Medical Research and Development Partnership in Russia
- Bayer advances research in the area of pulmonary hypertension
- AstraZeneca and PTC Therapeutics announce strategic oncology drug discovery collaboration